Tags : biosmilar)

Insights+ Key Biosimilars Events of January 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Pfizer’s Nivestym (filgrastim-aafi, biosmilar) Receives the US FDA Approval for

Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Nivestym and the reference product, Neupogen (filgrastim) Pfizer has received the US FDA’s fourth approvals for its biosimilar including Nivestym and will be available at a discount of wholesale acquisition cost (WAC) of Neupogen Nivestym (filgrastim-aafi, Neupogen) is a mAb, indicated to decrease the […]Read More